Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Lee Jackson | May 6, 2015 at 10:00 AM EDT

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the…

Chris Lange | May 6, 2015 at 9:30 AM EDT

Is Alexion Grossly Overpaying for Synageva?

Biotech giant Alexion Pharmaceuticals announced Wednesday morning that it will acquire Synageva BioPharma.

Chris Lange | May 5, 2015 at 10:50 AM EDT

Top Credit Suisse Major Pharma Stock Picks to Buy

Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.

Chris Lange | May 4, 2015 at 11:00 AM EDT

What Is Really Driving Array Higher

Array BioPharma released disappointing fiscal third-quarter earnings before the markets opened Monday morning.

Lee Jackson | May 4, 2015 at 9:05 AM EDT

2 Biotech Buyout Candidates as Antibiotics Stop Working

In a new report, the analysts at Stifel are very positive on two companies leading the charge against antibiotic-resistant "super…

Chris Lange | May 1, 2015 at 12:15 PM EDT

Can Immunomedics Double?

Immunomedics may be poised to make big moves going forward in 2015, according to Wells Fargo.

Lee Jackson | May 1, 2015 at 8:20 AM EDT

3 Biotech Stocks With Big Phase 3 Catalyst Data Due in 2015

Recently, biotech stocks have been getting stung pretty good, and now may be a good time to look at companies…

Chris Lange | Apr 30, 2015 at 4:30 PM EDT

Gilead Avoids the Earnings Hangman

Gilead Sciences reported better than expected first-quarter results Thursday after the markets closed.

Chris Lange | Apr 30, 2015 at 10:25 AM EDT

How the Inovio Secondary Crushed Its Shareholders

A lot of times when companies have secondary offerings the price takes a slight dip to accommodate the dilution and…

Lee Jackson | Apr 30, 2015 at 9:30 AM EDT

Why These 2 Biotech Stocks May Be Bought Out Soon

In a new report, Stifel sees two biotech stocks with near-term catalysts that could make takeover candidates soon.

Chris Lange | Apr 30, 2015 at 8:50 AM EDT

Is Celgene Stumped on Its Portfolio?

Celgene released mixed first-quarter results before the markets opened Thursday and shares were down in early trading.

Chris Lange | Apr 29, 2015 at 3:33 PM EDT

What to Expect From Gilead Earnings

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) will report its first-quarter earnings Thursday after the markets close. Thomson Reuters has consensus estimates…

Chris Lange | Apr 29, 2015 at 3:05 PM EDT

What to Expect From Celgene Earnings

ThinkstockCelgene Corp. (NASDAQ: CELG) is scheduled to release its first-quarter financial results before the markets open Thursday. Thomson Reuters has…

Jon C. Ogg | Apr 28, 2015 at 4:36 PM EDT

Will Schizophrenia and Bipolar Patients Trust Generic Abilify?

ThinkstockThe trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in…

Jon C. Ogg | Apr 28, 2015 at 8:15 AM EDT

Despite Currencies, Merck Delivers on Earnings

Merck has managed to beat its first-quarter earnings expectations, and handily at that.

1 … 263 264 265 266 267 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Is Alexion Grossly Overpaying for Synageva?

Top Credit Suisse Major Pharma Stock Picks to Buy

What Is Really Driving Array Higher

2 Biotech Buyout Candidates as Antibiotics Stop Working

Can Immunomedics Double?

3 Biotech Stocks With Big Phase 3 Catalyst Data Due in 2015

Gilead Avoids the Earnings Hangman

How the Inovio Secondary Crushed Its Shareholders

Why These 2 Biotech Stocks May Be Bought Out Soon

Is Celgene Stumped on Its Portfolio?

What to Expect From Gilead Earnings

What to Expect From Celgene Earnings

Will Schizophrenia and Bipolar Patients Trust Generic Abilify?

Despite Currencies, Merck Delivers on Earnings

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

These 3 S&P 500 ETFs Are Nearly Identical But After Doing the Math One of Them Saves You Money Over a Lifetime

Three Value Focused ETFs Pay Solid Dividends and Keep Outperforming the Market in 2026

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

These 3 S&P 500 ETFs Are Nearly Identical But After Doing the Math One of Them Saves You Money Over a Lifetime

Health and Healthcare Articles

All Health and Healthcare Articles

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Is Alexion Grossly Overpaying for Synageva?

Top Credit Suisse Major Pharma Stock Picks to Buy

What Is Really Driving Array Higher

2 Biotech Buyout Candidates as Antibiotics Stop Working

Can Immunomedics Double?

3 Biotech Stocks With Big Phase 3 Catalyst Data Due in 2015

Gilead Avoids the Earnings Hangman

How the Inovio Secondary Crushed Its Shareholders

Why These 2 Biotech Stocks May Be Bought Out Soon

Is Celgene Stumped on Its Portfolio?

What to Expect From Gilead Earnings

What to Expect From Celgene Earnings

Will Schizophrenia and Bipolar Patients Trust Generic Abilify?

Despite Currencies, Merck Delivers on Earnings

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

These 3 S&P 500 ETFs Are Nearly Identical But After Doing the Math One of Them Saves You Money Over a Lifetime

Three Value Focused ETFs Pay Solid Dividends and Keep Outperforming the Market in 2026

Featured Reads

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later